Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hybridon HYBN, for discussion of antisense drugs. -- Ignore unavailable to you. Want to Upgrade?

To: Bosco who wrote (17)	1/21/1998 5:20:00 AM
From: Peter Church	Read Replies (1) \| Respond to of 42

>>There is a likelihood that HYBN will join the rank of so many cos who have suffered such a fate.>> Could you explain what fate they suffered? I've been interested in this company since a pharmacist friend recommended it last summer. It has been a rotten investment, so far. I was hoping that the new capital would help it back on its feet. At least they have the ticker, HYBN, back.

To: Bosco who wrote (17)	1/21/1998 10:03:00 PM
From: Mounir Abouzakhm	Read Replies (3) \| Respond to of 42

Dear Bosco, Thanks for ansewring my post. I was hoping that another pharmacuetical company will believe in their technology and either buy or team with them. From your analysis, it seems that this is a wishful thinking. It is pitty because I understand that some of the researchres there are pretty good. I wonder how did the board of directors let something like this happen. I bought it at $5.5/share. Guess you were lucky that you did not buy any. Good luck. Mounir